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ABSTRACT
Caveolin-1(CAV-1) was demonstrated to be a tumor suppressor gene and 
be implicated in the development of breast cancer (BC). Numerous potentially 
functional polymorphisms in CAV-1 have been identified, but their effects on BC 
were not clear. This case-control study aims to evaluate the relationship between 
CAV-1 polymorphisms and BC risk. 560 BC patients and 583 healthy controls were 
enrolled in the present study, all from Chinese Han population. We detected 3 single 
nucleotide polymorphisms (rs3807987, rs1997623, and rs7804372) in CAV-1 using 
the Sequenom MassARRAY method. The association between CAV-1genotypes and BC 
risk was assessed in six genetic models by calculating the odds ratio (OR) and 95% 
confidence intervals (95% CIs) with χ2-test. The CAV-1 rs3807987 polymorphism was 
observed to increase the risk of BC And the A allele of rs3807987 relates to a larger 
tumor size (≥2cm) and lower incidence of PR-positive BC while the AA genotype of 
rs7804372 associates with a higher ER and Her-2 positive rate among BC patients. In 
addition, Ars1997623Grs3807987Trs7804372 haplotype was linked to a decreased risk of BC (OR 
=0.64, 95%CI=0.44-0.93), whereas Crs1997623Ars3807987Trs7804372 haplotype was related to 
an increased BC risk (OR =1.74, 95%CI=1.04-2.92). Our study suggests that CAV-1 
rs3807987 can increase the BC risk among Chinese Han women. And the rs3807987 
and rs7804372 in CAV-1 may serve as predictors for prognosis of BC.
INTRODUCTION
Breast cancer (BC) is the most common cancer type 
and the main cause of cancer death in women all over the 
world [1]. In China, it also ranks the top of all the female 
cancers. In 2012, the morbidity and mortality of BC in 
China is about 0.221‰ and 0.054‰ respectively [2]. 
BC is an extremely heterogeneous disease. And multiple 
factors including hereditary and environmental factors 
are associated with its carcinogenesis. Genetic factors are 
believed to play a vital role in the development of BC. 
About 5-10% of all the BC cases are hereditary, caused by 
mutations in susceptibility genes [3].
CAV-1 gene is located on human chromosome 
7(7q31.1) and contains 3 exons. It encodes the protein 
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caveolin-1, which is the essential structural component of 
caveolae [4, 5]. Caveolae is a special type of lipid raft, 
being rich in proteins and lipids. They are small vesicular 
invaginations of the plasma membrane in most cell 
types, especially in endothelial cells and adipocytes. And 
caveolae was shown to have several functions in signal 
transduction, cellular proliferation and differentiation, and 
contributes to tumorigenesis and tumor progression [6, 7]. 
Caveolin-1 has been implicated in the pathogenesis of cell 
transformation, oncogenesis and metastasis. Studies have 
shown that caveolin-1 can suppress breast cancer and its 
expression in BC tissue and cells were reduced compared 
with normal tissues [8, 9].
It has been indicated that CAV-1 functions as 
a tumor suppressor gene and is mutated in up to 16-
20% of breast cancers. It is also a inhibitor of the 
Ras-p42/44 mitogen-activated kinase pathway, which 
involves in cell cycle progression and was shown to 
be overexpressed in both primary and metastatic breast 
cancer cells [10, 11]. The loss of CAV-1 can specifically 
up-regulate cyclin D1 and increase ERα expression, 
thus enhance estrogen-stimulated growth of BC cells 
[12]. All these evidence suggested that mutations in 
human CAV-1 gene are involved in the BC onset and 
progression.
Single nucleotide polymorphism (SNP) is the 
most common form of mutation in the genome and is 
supposed to play a crucial role in genetic susceptibility 
to cancer. Numerous potentially functional SNPs in 
CAV-1 have been identified through sequencing. Here, 
we chose 3 polymorphisms (rs3807987, rs1997623, and 
rs7804372) which are annotated in NCBI databases. 
These SNPs have been investigated in multiple cancer 
types including hepatocellular carcinoma, gastric 
cancer and prostate cancer. And they were found linked 
to cancer risk [13–15]. But their associations with 
BC susceptibility have not been fully understood. To 
investigate the relationship of CAV-1 polymorphisms and 
BC risk, we conducted a case–control study in Chinese 
Han population.
RESULTS
Characteristics of study subjects
There were no significant differences in age, 
menopausal status, and procreative times between cases 
and controls(P>0.05). However, body mass index (BMI) 
values in two groups were significantly different. BMI 
values of BC patients were lower than those of healthy 
controls (P=0.038), which suggests that BMI may be a 
confounding factor. So, the results of additional analyses 
were adjusted for BMI. The detailed information of the 
subjects was described in our previous study [16].
Association between CAV-1 polymorphisms and 
BC risk
As shown in Table 1, the genotype distributions 
of the three CAV-1 SNPs (rs3807987, rs1997623, and 
rs7804372) in the control group were all conformed 
to HWE (P=0.111, 0.356 and 0.125 respectively). The 
rs3807987 polymorphism was related to increased BC risk 
in the heterozygous, dominant, and overdominant models 
(GA vs. GG: OR=1.41, 95%CI=1.09-1.82, P=0.008; 
GA+AA vs. GG: OR= 1.36, 95%CI= 1.07-1.74, P=0.013; 
GA vs. GG + AA: OR=1.40, 95%CI=1.09-1.81, P=0.008). 
Whereas no obvious relationship was found between 
the other two polymorphisms and BC risk. We further 
conducted subgroup analyses by age and menopausal 
status. However, neither of the polymorphisms was 
found to associate with BC risk in any genetic models 
(Supplementary Table 1 and Supplementary Table 2).
CAV-1 polymorphisms and clinicopathological 
features of BC
We also investigated the relationship of CAV-1 SNPs 
with clinical and histological features of BC, including 
tumor size, lymph node metastasis, and the statuses of 
estrogen receptor (ER), progestogen receptor (PR), human 
epidermal growth factor receptor 2 (Her-2), and Ki67. As 
for rs3807987, we found that the A allele was related to 
a larger tumor size (≥2cm) in BC patients (GA+AA vs. 
GG: OR= 1.52, 95%CI= 1.05-2.21; A vs. G: OR= 1.48, 
95%CI=1.07-2.03), and lower incidence of PR-positive 
breast cancer (GA+AA vs. GG: OR= 0.69, 95%CI= 0.49-
0.98; A vs. G: OR= 0.72, 95%CI= 0.54- 0.96) (Table 2). For 
rs7804372, BC patients with AA genotype are more likely 
to have ER- positive tumors than TT and TA genotype 
carriers (recessive model: OR =2.15, 95%CI=1.02-4.54). 
Moreover, the AA genotype of rs7804372 associates 
with a higher Her-2 positive rate compared with TT and 
TT+TA genotypes (Table 3). No significant association 
exists between the rs1997623 polymorphism and any of 
the clinical parameters (Supplementary Table 3).
Association between CAV-1 haplotypes and BC 
risk
To evaluate the effect of SNPs interaction on 
BC risk, we performed haplotype analysis. The allele 
distributions and frequencies of the CAV-1 haplotypes 
are presented in Table 4, and the most frequent haplotype 
in controls was chosen as a reference. We observed that 
the Ars1997623Grs3807987Trs7804372 haplotype was associates 
with a reduced BC risk (OR =0.64, 95%CI=0.44-0.93, 
P=0.018) compared with the Crs1997623Grs3807987Trs7804372 wild 
type, whereas the Crs1997623Ars3807987Trs7804372 haplotype was 
related to a higher risk of BC (OR =1.74, 95%CI=1.04-
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Table 1: Genotype frequencies of Cav-1 polymorphism in cases and controls
Model Genotype Cases (n,%) Control (n,%) P† OR (95% CI) P (HWE)
rs3807987 (G14713A)
Co-dominant GG 345 (61.61%) 400 (68.61%) 1.00 0.111
Heterozygote GA 193 (34.46%) 159 (27.27%) 0.008 1.41(1.09-1.82)
Homozygote AA 22 (3.93%) 24 (4.12%) 0.841 1.06 (0.59-1.93)
Dominant GG 345 (61.61%) 400 (68.61%) 1.00
GA+AA 215 (38.39%) 183 (31.39%) 0.013 1.36 (1.07-1.74)
Recessive GG+GA 538 (96.07%) 559 (95.88%) 1.00
AA 22 (3.93%) 24 (4.12%) 0.872 0.95 (0.53-1.72)
Overdominant GG + AA 367 (65.54%) 424 (72.73%) 1.00
GA 193 (34.46%) 159 (27.27%) 0.008 1.40 (1.09-1.81)
Allele G 883 (78.84%) 959 (82.25%) 1.00
A 237 (21.16%) 207 (17.75%) 0.040 1.24 (1.01-1.53)
rs1997623 (C239A)
Co-dominant CC 507 (90.54%) 509 (87.31%) 1.00 0.356
Heterozygote CT 51 (9.11%) 70 (12.01%) 0.107 0.73 (0.50-1.07)
Homozygote TT 2 (0.36%) 4 (0.67%) 0.418 0.50 (0.09-2.75)
Dominant CC 507 (90.54%) 509 (87.31%) 1.00
CT+TT 53 (9.46%) 74 (12.69%) 0.083 0.72 (0.50-1.04)
Recessive CC+CT 558 (99.64%) 579 (99.31%) 1.00
TT 2 (0.36%) 4 (0.67%) 0.442 0.52 (0.10-2.84)
Overdominant CC+TT 509 (90.89%) 513 (91.61%) 1.00
CT 51 (9.11%) 70 (12.01%) 0.111 0.73 (0.50-1.08)
Allele C 1065 (95.09%) 1088 (93.31%) 1.00
T 55 (4.91%) 78 (6.69%) 0.069 0.72 (0.51-1.02)
rs7804372* (T29107A)
Co-dominant TT 317 (56.61%) 338 (58.08%) 1.00 0.125
Heterozygote AT 207 (36.96%) 202 (34.71%) 0.482 1.09(0.85-1.40)
Homozygote AA 36 (6.43%) 42 (7.22%) 0.708 0.91 (0.57-1.46)
Dominant TT 317 (56.61%) 338 (58.08%) 1.00
AT+AA 243 (43.39%) 244 (41.92%) 0.616 1.06 (0.84-1.34)
Recessive TT+AT 524 (93.57%) 540(92.78%) 1.00
AA 36 (6.43%) 42 (7.22%) 0.598 0.88 (0.56-1.40)
Overdominant TT+AA 353 (63.04%) 380 (65.29%) 1.00
AT 207 (36.96%) 202 (34.71%) 0.427 1.10 (0.87-1.41)
Allele T 841 (75.09%) 878 (75.43%) 1.00
A 279 (24.91%) 286 (24.57%) 0.851 1.018 (0.84-1.23)
† Adjusted for age and body mass index. rs7804372*: controls missing, n = 1.
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2.92, P= 0.033). No relationship was found between other 
haplotypes and BC risk.
DISCUSSION
Caveolin-1, encoded by CAV-1 gene, is a 21- to 
24-kDa integral membrane protein. It is enriched in 
specialized plasma membranes invaginations called 
caveolae, which are found in many cell types. As an 
intracellular structural protein, caveolin-1 regulates several 
important signaling transduction related to BC including 
ER, EGFR, Her2/neu, TGF-β, and mTOR pathways [5, 
17]. Since genetic factors play a crucial role in human 
breast carcinogenesis, polymorphisms in genes that 
encode proteins involved in the BC development can act 
as biomarkers and may even turn out to be useful targets 
for particular therapeutic approaches to BC [3]. Hence, we 
designed this study to investigate the association of CAV-1 
polymorphisms with BC susceptibility.
A number of studies have explored the associations 
between CAV-1 genetic polymorphisms and the risk of 
various cancer types including hepatocellular carcinoma 
[13], gastric cancer [14], esophageal cancer [18], 
colorectal cancer [19], renal cell carcinoma [20], prostate 
cancer [15], bladder cancer [21] and leukemia [22]. We 
also found one study investigated the effect of CAV-1 
SNPs on BC susceptibility by Liu et al. In Liu’s study, they 
determined the six SNPs in CAV-1 (rs1997623, rs3807987, 
12672038, rs3757733, rs7804372, and rs3807992) and 
assessed their association with BC risk. The results 
indicated that the genotype distributions of rs3807987 
and rs7804372 were significantly different in BC patients 
and healthy controls. The GG/AT or GG/AA haplotypes 
associated with a lower risk of BC (OR=0.69, 95% 
CI=0.57-0.92), whereas the AG/TT haplotype conferred 
a higher risk of BC (OR=1.50, 95% CI=1.14-2.12)[23]. 
The present study has some difference with Liu’s study. 
First, we assessed three SNPs in CAV-1 which Liu et al. 
also investigated, but the results were different. Our study 
showed that only rs3807987 related to BC susceptibility. 
The GA or GA+AA genotypes of rs3807987 may 
increase the risk of BC compared with GG or GG+AA 
Table 2: The associations between the Cav-1 rs3807987 polymorphism and clinical characteristics of breast cancer
Variables GG GA AA
Heterozygote
Adjusted OR 
(95% CI)
Homozygote
Adjusted OR 
(95% CI)
Dominant
Adjusted OR 
(95% CI)
Recessive
Adjusted OR 
(95% CI)
Allele
Adjusted OR 
(95% CI)
Tumor size
<2 cm 128 56 4 1.00
≥2 cm 217 137 18 1.44(0.99-2.11) 2.65(0.88-8.02) 1.52(1.05-2.21) 2.34(0.78-7.01) 1.48(1.07-2.03)
LN metastasis
Negative 151 74 11 1.00
Positive 194 119 11 1.25(0.87-1.79) 0.78(0.33-1.84) 1.19(0.84-1.68) 0.72(0.31-1.69) 1.09(0.81-1.46)
ER
Negative 147 92 8 1.00
Positive 198 101 14 0.82(0.5721.16) 1.30(0.53-3.18) 0.85(0.61-1.20) 1.40(0.58-3.39) 1.13(0.85-1.52)
PR
Negative 145 97 13 1.00
Positive 200 96 9 0.72(0.50-1.02) 0.50(0.21-1.21) 0.69(0.49-0.98) 0.57(0.24-1.35) 0.72(0.54-0.96)
Her-2
Negative 242 132 15 1.00
Positive 103 61 7 1.09(0.74-1.59) 1.10(0.43-2.77) 1.09(0.75-1.57) 1.06(0.43-2.67) 1.07(0.78-1.46)
Ki67
< 14% 116 69 10 1.00
≥14% 229 124 12 0.91(0.63-1.32) 0.61(0.26-1.45) 0.87(0.61-1.24) 0.63(0.27-1.48) 0.86(0.64-1.16)
OR: odds ratio; CI: confidence interval; LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; Her-2: human 
epidermal growth factor receptor-2.
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genotypes. The difference may be due to sample size 
and divergence of the population. Liu et al. investigated 
a Taiwanese population, whereas the volunteers in 
our study subjects all come from northwest of China. 
Second, we further explored the association of CAV-1 
polymorphisms and clinical features of BC. Our results 
suggested that rs3807987 polymorphism in CAV-1 was 
associated with tumor size and PR status while rs7804372 
polymorphism was linked to ER and Her-2 status. The 
underlying mechanisms for this finding are unknown by 
now, which can be a promising field for future studies. We 
also performed stratified analyses by age and menopausal 
status, though there was no significant difference in the 
subgroups.
Previous studies have demonstrated that the 
expression of CAV-1 in both mRNA and protein levels is 
down-regulated in breast cancer and CAV-1 re-expression 
can inhibit the growth and the invasive and migratory 
potential of BC cells [12, 24]. In addition, the decreased 
expression of caveolin-1 in BC is significantly associated 
with advanced tumor stage, invasion or metastasis, 
early recurrence, and poor outcome [5]. The underlying 
mechanism is not fully elucidated. Some studies suggested 
that mutational CAV-1 can induce cellular transformation, 
activate MAPK signaling pathway and alter actin networks 
in BC cells, thus promote invasion-ability of BC. And 
aberrant promoter methylation of CAV-1 may also play 
a role in the regulation of BC onset [9, 25]. Our study 
proved the role of CAV-1 in breast cancer susceptibility 
and revealed its relation with clinical characteristic of BC. 
However, there are some limitations in our study should 
be noticed. Firstly, selection bias may exist since this is 
Table 3: The associations between the Cav-1 rs7804372 polymorphism and clinical characteristics of breast cancer
Variables TT AT AA
Heterozygote
Adjusted OR
(95% CI)
Homozygote
Adjusted OR
(95% CI)
Dominant
Adjusted OR
(95% CI)
Recessive
Adjusted OR
(95% CI)
Allele
Adjusted OR
(95% CI)
Tumor size
<2 cm 103 70 15 1.00
≥2 cm 214 137 21 0.942(0.650-1.366)
0.674(0.334-
1.361)
0.895(0.628-
1.274)
0.690(0.347-
1.372)
0.874(0.658-
1.161)
LN metastasis
Negative 140 77 19 1.00
Positive 177 130 17 1.335(0.933-1.911)
0.708(0.355-
1.412)
1.211(0.862-
1.701)
0.632(0.321-
1.245)
1.052(0.799-
1.385)
ER
Negative 141 96 10 1.00
Positive 176 111 26 0.926(0.652-1.317)
2.083(0.972-
4.464)
1.035(0.739-
1.450)
2.147(1.015-
4.542)
1.147(0.872-
1.509)
PR
Negative 134 101 20 1.00
Positive 183 106 16 0.768(0.540-1.093)
0.586(0.293-
1173)
0.738(0.528-
1.033)
0.651(0.330-
1.283)
0.765(0.583-
1.004)
Her-2
Negative 216 155 18 1.00
Positive 101 52 18 1.717(0.484-1.063)
2.139(1.068-
4.284)
0.865(0.601-
1.246)
2.425(1.229-
4.786)
1.065(0.795-
1.426)
Ki67
< 14% 114 72 9 1.00
≥14% 203 135 27 1.053(0.730-1.519)
1.685(0.766-
3.707)
1.123(0.790-
1.597)
1.651(0.760-
3.585)
1.205(0.873-
1.553)
OR: odds ratio; CI: confidence interval; LN: lymph node; ER: estrogen receptor; PR: progesterone receptor; Her-2: human 
epidermal growth factor receptor-2.
Oncotarget91659www.impactjournals.com/oncotarget
a hospital-based case-control study and all the subjects 
were from the same hospital. Secondly, the sample size 
was inadequate for a stratified analysis of BC subtypes. 
Thirdly, the effect of other predisposing factors such as 
family heredity history, environmental exposures, alcohol 
consumption, and lifestyle was not assessed due to lack 
of data. Besides, our study is a clinical research and lacks 
functional experiments to support the results. Thus, future 
population-based studies are needed to assess these factors 
as well for a more accurate evaluation of the effect of CAV-
1 genetic polymorphisms on BC risk. And, the functions 
of these polymorphisms and the underlying mechanisms 
need to be explored in subsequent studies.
In conclusion, the current study showed that 
CAV-1 polymorphism rs3807987 associates with BC 
susceptibility in Chinese Han population. The Crs1997623A
rs3807987Trs7804372 haplotype of CAV-1 may increase the risk 
of BC whereas the Ars1997623Grs3807987Trs7804372 haplotype 
may be protective for the onset of BC. Moreover, CAV-
1 rs3807987 and rs7804372 polymorphisms were related 
to tumors size and ER/PR /Her-2 status, which may act 
as predictors for BC prognosis and effect of treatment. 
Further large prospective studies and functional studies 
are needed in order to provide more evidence about the 
influence of CAV-1 genetic variants on BC risk, and to 
explore the possible molecular mechanism.
MATERIALS AND METHODS
Study subjects
This study was approved by the Ethics Committee 
of the Second Affiliated Hospital of Xi’an Jiaotong 
University (Xi’an, China). Patients with BC were selected 
from the Department of Oncology. At the mean time, 
healthy individuals who came to the same hospital for 
a checkup were recruited as controls. All the cases were 
confirmed by histology or pathology and the controls were 
matched based on age and menopausal status. Patients 
who had received chemotherapy or radiotherapy before 
surgery or had another type of cancer were excluded [26, 
27]. Finally, 1143 subjects (560 cases and 583 controls) 
were enrolled in the study. All the subjects were unrelated 
Chinese Han females. They were well informed of the 
purpose of our study and all of them signed a consent 
form.
DNA extraction and genotyping
The blood samples of all the subjects were collected 
in EDTA- coating tubes and stored at−80°C for further 
use. Genomic DNA was extracted from peripheral 
blood samples with the Universal Genomic DNA 
Table 4: The haplotype analysis of Cav-1 polymorphisms and breast cancer risk
Haplotypes Cases
(N=1120) n, %
Controls
(N=1166) n, %
OR
(95% CI) prs1997623 rs3807987 rs7804372
C G T 746 (66.61%) 779(66.81%) 1.00 (reference)
C A A 189(16.88%) 183(15.69%) 1.08(0.86-1.35) 0.514
C G A 90(8.04%) 102(8.75%) 0.92 (0.68-1.25) 0.594
A G T 47 (4.20%) 77(6.60%) 0.64(0.44-0.93) 0.018
C A T 40(3.57%) 24(2.06%) 1.74(1.04-2.92) 0.033
A A T 8(0.71%) - - -
A G T - 1(0.09%) - -
Table 5: Primers used for this study
SNP_ID 1st-PCRP 2nd-PCRP UEP_SEQ
rs3807987 ACGTTGGATGTGTGGC  ATCCAGATGATCTC
ACGTTGGATGGAATT
TGCCTGTCCTGTCTG CTGTCTGCCAGACAC
rs1997623 ACGTTGGATGGTGAA G AGAAGCCAGGAATG
ACGTTGGATGCTTT
TCCGTGTCCTCCTAGC CCCTTAGCTCAGGGGC TCCC
rs7804372 ACGTTGGATGCTGAATCCAACAAAGCTCGG
ACGTTGGATGAAT
CTGCTGAAGCAGCTGTG GTGTGCTTTGATTGATG TGGA
PCRP: polymerase chain reaction primer; SNP:single nucleotide polymorphism; UEP-SEQ: unextension primer sequence.
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Extraction Kit (version 3.0; TaKaRa Bio Inc., Kusatsu, 
Japan) following the manufacturer’s instructions. DNA 
quantity was evaluated by spectrometry (DU530 UV/
VIS spectrophotometer, Beckman Instruments, Fullerton, 
CA). Tree tag-SNPs (rs3807987, rs1997623, and 
rs7804372) were selected in our study using the data from 
HapMap database. We only considered SNPs of which 
minor allele frequency (MAF) was greater than 0.01. A 
multiplexed SNP MassEXTEND assay was designed by 
the Sequenom MassARRAY Assay Design 3.0 Software 
(Agena Bioscience, Inc., San Diego, CA). SNP genotyping 
was performed by the SequenomMassARRAY RS1000. 
Primers for the three SNPs are shown in Table 5. Data was 
analysed by Sequenom Type 4.0 Software (Sequenom, 
Inc).
Statistical analysis
The allele and genotype frequencies of CAV-1 
polymorphisms were counted directly. And the Hardy-
Weinberg equilibrium (HWE) for each SNP in the control 
group was examined using Pearson χ2-test. The differences 
of allele and genotype distribution for each SNP between 
cases and controls were also determined by Pearson χ2-
test while the differences in clinical characteristics were 
assessed by Student t-test or χ2-test. A two-sided P-value < 
0.05 was considered statistically significant in all the tests. 
Associations of CAV-1 polymorphisms with BC risk and 
the patients’ clinical characteristics were estimated with 
an odds ratio (OR) and 95% confidence interval (CI) in 
the codominant model (homozygous model: aa vs. AA; 
heterozygous model: Aa vs. AA), the dominant model 
(AA vs. Aa+aa), the recessive model (aa vs. AA+Aa), 
the overdominant model (Aa vs. AA+ aa), and the allele 
model (a vs. A) respectively (A: the major allele, a: the 
minor allele). And logistic regression analysis was used to 
adjust for confounding factors. PHASE v2.1 software was 
used to perform the haplotype analysis. All the statistical 
analyses were accomplished using SPSS 22.0 software 
(IBM Corporation, NY, USA).
Abbreviations
CAV-1: caveolin-1; BC: breast cancer; SNP: single 
nucleotide polymorphism; OR: odds ratio; 95% CI: 95% 
confidence interval; BMI: body mass index; HWE: Hardy-
Weinberg equilibrium; LN: lymph node; ER: estrogen 
receptor; PR: progesterone receptor; Her-2: human 
epidermal growth factor receptor-2.
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